Highlights
- Combining CA125 and NT-proBNP markedly improves risk prediction for cardiovascular mortality, all-cause mortality, and rehospitalization in acute heart failure (AHF).
- High levels of both biomarkers identify patients at substantially elevated risk, supporting their joint use in clinical decision-making.
- This prospective Vietnamese cohort provides region-specific evidence for biomarker-guided management in AHF.
Study Background and Disease Burden
Specialty calculators
For clinical reference; use professional judgment.
